Multidimensional alcohol craving scale and [123I] lodobenzamide SPECT as predictors of early relapse in alcohol-dependent patients
DOI:
https://doi.org/10.20882/adicciones.159Keywords:
I123iodobenzamide-single photon emission computerized tomography (SPECT), multidimensional alcohol craving scale (MACS), time to first heavy drinking day (TFHD), alcohol-dependenceAbstract
Background: The Multidimensional Alcohol Craving Scale (MACS) and Single Photon Emission Computerized Tomography (SPECT) with 123I-iodobenzamide (123I-IBZM) can be useful tools for assessing relapse risk in early recovery from alcohol-dependency. The aim of this study was to assess possible relationships between MACS score, 123I-IBZM binding and time to first heavy drinking day (TFHD) after detoxification treatment. Methods: Nineteen alcohol-dependent in-patients were evaluated by MACS scale and an 123I-IBZM-SPECT, performed following alcohol detoxification treatment. At discharge, participants were advised to take naltrexone 50 mg/day for relapse prevention. TFHD was assessed over a 12-week follow up. Results: The MACS score at the beginning of the detoxification process and naltrexone treatment after detoxification were independent predictive factors for TFHD. Conclusions: The MACS scale is a better predictor of TFHD than IBZM binding. It is simple, non-invasive and inexpensive and appears to be a useful instrument both for clinical practice and for research.References
Heinz A, Dufeu P, Kuhn S, Dettling M, Gräf K Kürten I, Rommelspacher
H, Schmidt LG. Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol dependent patients. Arch Gen Psychiatry
; 53: 1123-1128.
Volkow ND; Fowler JS, Wang G-J, Hitzemann R, Logan J, Schyler D,
Dewey S, Wolf AP. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993; 14: 169-177.
Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, Pappas N, Shea C, Piscani K. Decreases in dopamine receptors but not
in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996; 20:
-1598.
Rosetti ZL, Melis F, Carboni S, Diana M, Gessa GL. Alcohol withdrawal
in rats is associated with a marked fall in extraneuronal dopamine.
Alcohol Clin Exp Res 1992; 16: 529-532.
Heinz A, Siessmeier T, Wrase J, Bucholz HG, Grüder G, Kamakura Y,
Cumming P, Schreckenberger M, Smolka MN, Rösch F, Mann K, Artenstein P. Correlation of alcohol craving with striatal dopamine synthesis capacity and D-2/3 receptor availability: a combined [18F] DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 2005; 162: 1515-1520.
Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegels L,
Talbot P, Evans S, Krystal J, Laruelle M, Abi-Dargam A. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005; 58: 779-786.
Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the
frontal cortex. Am. J. Psychiatry 2002; 159: 1642-1652.
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of
motivation and choice. Am J Psychiatry 2005; 162: 1403-1413.
Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grüsser SM, Flor
H, Braus DF, Buchholz HG, Gründer G, Schreckenberger M, Smolka MN, Rösch F, Mann K, Bartenstein P. Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 2004; 161: 1783-1789.
Guardia J, Trujols J, Burguete T, Luquero E, Cardús M. The Impaired
Response Inhibition Scale for Alcoholism (IRISA). Development and
psychometric properties of a new scale for abstinence-oriented
treatment of alcoholism. Alcohol Clin Exp Res 2007; 31: 269-275.
Kung HF, Alavi A, Chang W et al. In vivo SPECT imaging of CNS D-2
dopamine receptors: Initial studies with Iodine-123-IBZM in humans. J Nucl Med 1990; 31: 573-579.
Verhoeff NP, Bobeldijk M, Feenstra MGP et al. In vitro and in vivo D2
dopamine receptor binding with (123I-IBZM) in rat and human brain. Nucl Med Biol 1991; 18: 837-846.
Guardia J, Catafau AM, Batlle F, Martín JC, Segura L, Gonzalvo B, Prat G, Carrió I, Casas M. Striatal dopaminergic D2 receptor density, measured by 123I-IBZM SPECT, might predict treatment outcome in alcohol dependent patients. Am J Psychiatry 2000; 157: 127-129.
Guardia-Serecigni J, Segura García L, Gonzalvo Cirac B, Trujols Albet J, Tejero Pociello A, Suárez González A, Martí Gil A. Estudio de validación
de la Escala Multidimensional de Craving de Alcohol (Escala EMCA).
Med Clin (Barc) 2004; 123: 211-216.
Guardia-Serecigni J, Luquero Vived E, Siñol Llosa N, Burguete Uriol T,
Cardús Moya M. Utilidad de la Escala Multidimensional de Craving de
Alcohol (EMCA) en la práctica clínica. Adicciones 2006; 18: 265-273.
Czoty PW, Riddick NV, Gage HD, Sandrige N, Nader SH, Garg S, Bounds M, Garg PK, Nader MA. Effect of menstrual cycle phase on dopamine D2 receptor availability in female cynomolgus monkeys. Neuropsychopharmacol 2009; 34: 548-554.
Brücke T, Pdreka I, Angelberger S, Wenger S, Topitz A, Küfferle B,
Müller Ch, Deecke L. Dopamine D2 receptor imaging with SPECT: studies
in different neuropsychiatryc disorders. J Cereb Blood Flow Metab
; 11: 220-228.
Volkow ND; Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy
individuals. Am J Psychiatry 1998; 155: 344-349.
Rubio Valladolid G, Urosa Sanz B, Santo-Domingo Carrasco J (1998)
Validación de la escala de la intensidad de la dependencia al alcohol
(EIDA). Psiquiatr Biol 5 Suppl 1: 44-47.
Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramírez M, Mengual I,
Gonzalvo B, Segura L, Trujols J, Casas M. A double-blind, placebo- controlled study of naltrexone in the treatment of alcohol-dependence
disorder. Results from a multicenter clinical trial. Alcohol Clin Exp Res
; 26: 1381–1387.
Bouza C, Magro A, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a
systematic review. Addiction 2004; 99: 811-828.
Anton RF, Myric H, Baros AM, Latham PK, Randall PK, Wright TM,
Stewart SH, Waid R, Malcom R. Efficacy of a combination of flumazenil
and gabapentin in the treatment of alcohol dependence: relationship to the alcohol withdrawal symptoms. J Clin Psychopharmacol 2009; 29:334-342.
Oslin DW, Cary M, Slaymaker V, Colleran CX, Blow FC. Daly ratings
measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking. Drug Alcohol Depend 2009; 103: 131-136.
Heinz A, Beck A, Grüsser SM, Grace AA, Wrase J Identifying the neural
circuitry of alcohol craving and relapse vulnerability. Addict Biol 2009;
: 108-118.
